Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Cross-over Phase 2 Study of the Safety and Efficacy of Two Dose Levels of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Locally Advanced Unresectable or Metastatic Pancreatic Adenocarcinoma

Next Previous
X
Search
Trial Profile

A Randomized Cross-over Phase 2 Study of the Safety and Efficacy of Two Dose Levels of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Locally Advanced Unresectable or Metastatic Pancreatic Adenocarcinoma

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 14 Jan 2020

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Evofosfamide (Primary) ; Gemcitabine
  • Indications Adenocarcinoma; Pancreatic ductal carcinoma
  • Focus Therapeutic Use
  • Sponsors Threshold Pharmaceuticals

    • Most Recent Events

    • 04 Jun 2018 Results of comparison of pharmacokinetic data from MAESTRO trial to that of a phase II (404 study) were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2018, according to a Molecular Templates media release.
    • 16 May 2018 According to a Molecular Templates media release, interim results will be presented at t the American Society of Clinical Oncology (ASCO) Annual Meeting 2018.
    • 26 Jan 2013 Results presented at the 2013 Gastrointestinal Cancers Symposium.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top